These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 25608910)

  • 1. Chromogenic assays for measurement of rivaroxaban from EDTA anticoagulated plasma samples.
    Du S; Krämer S; Giese C; Weiss C; Wehling M; Krämer R; Harenberg J
    Thromb Haemost; 2015 May; 113(5):1149-51. PubMed ID: 25608910
    [No Abstract]   [Full Text] [Related]  

  • 2. Is anti-factor Xa chromogenic assay for Rivaroxaban appropriate in clinical practice? Advantages and comparative drawbacks.
    Bardy G; Fischer F; Appert A; Baldin B; Stève M; Spreux A; Lavrut T; Drici MD
    Thromb Res; 2015 Aug; 136(2):396-401. PubMed ID: 26058941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls.
    Samama MM; Contant G; Spiro TE; Perzborn E; Guinet C; Gourmelin Y; Le Flem L; Rohde G; Martinoli JL;
    Thromb Haemost; 2012 Feb; 107(2):379-87. PubMed ID: 22187012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determination of rivaroxaban by different factor Xa specific chromogenic substrate assays: reduction of interassay variability.
    Harenberg J; Krämer R; Giese C; Marx S; Weiss C; Wehling M
    J Thromb Thrombolysis; 2011 Oct; 32(3):267-71. PubMed ID: 21811937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ex vivo effects of low-dose rivaroxaban on specific coagulation assays and coagulation factor activities in patients under real life conditions.
    Mani H; Hesse C; Stratmann G; Lindhoff-Last E
    Thromb Haemost; 2013 Jan; 109(1):127-36. PubMed ID: 23138190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accuracy and consistency of anti-Xa activity measurement for determination of rivaroxaban plasma levels.
    Studt JD; Alberio L; Angelillo-Scherrer A; Asmis LM; Fontana P; Korte W; Mendez A; Schmid P; Stricker H; Tsakiris DA; Wuillemin WA; Nagler M
    J Thromb Haemost; 2017 Aug; 15(8):1576-1583. PubMed ID: 28574652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of laboratory assays to measure rivaroxaban--an oral, direct factor Xa inhibitor.
    Samama MM; Martinoli JL; LeFlem L; Guinet C; Plu-Bureau G; Depasse F; Perzborn E
    Thromb Haemost; 2010 Apr; 103(4):815-25. PubMed ID: 20135059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heparin-Calibrated Chromogenic Anti-Xa Activity Measurements in Patients Receiving Rivaroxaban: Can This Test Be Used to Quantify Drug Level?
    Gosselin RC; Francart SJ; Hawes EM; Moll S; Dager WE; Adcock DM
    Ann Pharmacother; 2015 Jul; 49(7):777-83. PubMed ID: 25855705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Test of the month: The chromogenic antifactor Xa assay.
    Gehrie E; Laposata M
    Am J Hematol; 2012 Feb; 87(2):194-6. PubMed ID: 22081480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A cross-sectional pharmacodynamic study based on peak and trough plasma levels.
    Francart SJ; Hawes EM; Deal AM; Adcock DM; Gosselin R; Jeanneret C; Friedman KD; Moll S
    Thromb Haemost; 2014 Jun; 111(6):1133-40. PubMed ID: 24401946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accurate determination of rivaroxaban levels requires different calibrator sets but not addition of antithrombin.
    Mani H; Rohde G; Stratmann G; Hesse C; Herth N; Schwers S; Perzborn E; Lindhoff-Last E
    Thromb Haemost; 2012 Jul; 108(1):191-8. PubMed ID: 22534775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An optimised, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasma.
    Samama MM; Amiral J; Guinet C; Perzborn E; Depasse F
    Thromb Haemost; 2010 Nov; 104(5):1078-9. PubMed ID: 20806114
    [No Abstract]   [Full Text] [Related]  

  • 13. Effects of Rivaroxaban Therapy on ROTEM Coagulation Parameters in Patients with Venous Thromboembolism.
    Chojnowski K; Górski T; Robak M; Treliński J
    Adv Clin Exp Med; 2015; 24(6):995-1000. PubMed ID: 26771971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-coagulation assessment with prothrombin time and anti-Xa assays in real-world patients on treatment with rivaroxaban.
    Königsbrügge O; Quehenberger P; Belik S; Weigel G; Seger C; Griesmacher A; Pabinger I; Ay C
    Ann Hematol; 2015 Sep; 94(9):1463-71. PubMed ID: 26025632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interference of rivaroxaban in one-stage and chromogenic factor VIII:C assays.
    Tichelaar V; de Jong H; Nijland H; Kluin-Nelemans H; Meijer K; Mulder A
    Thromb Haemost; 2011 Nov; 106(5):990-2. PubMed ID: 21901233
    [No Abstract]   [Full Text] [Related]  

  • 16. Effects of EDTA on routine and specialized coagulation testing and an easy method to distinguish EDTA-treated from citrated plasma samples.
    Crist RA; Gibbs K; Rodgers GM; Smock KJ
    Lab Hematol; 2009; 15(4):45-8. PubMed ID: 19923105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of rivaroxaban in human plasma samples.
    Harenberg J; Erdle S; Marx S; Krämer R
    Semin Thromb Hemost; 2012 Mar; 38(2):178-84. PubMed ID: 22422332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors.
    Verhoef D; Visscher KM; Vosmeer CR; Cheung KL; Reitsma PH; Geerke DP; Bos MHA
    Nat Commun; 2017 Sep; 8(1):528. PubMed ID: 28904343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rivaroxaban Levels in Patients' Plasmas are Comparable by Using Two Different Anti Xa Assay/Coagulometer Systems Calibrated with Two Different Calibrators.
    Martinuzzo ME; Duboscq C; Lopez MS; Barrera LH; Vinuales ES; Ceresetto J; Forastiero RR; Oyhamburu J
    Clin Lab; 2018 Jun; 64(6):1091-1095. PubMed ID: 29945328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The mechanism of action of rivaroxaban--an oral, direct Factor Xa inhibitor--compared with other anticoagulants.
    Samama MM
    Thromb Res; 2011 Jun; 127(6):497-504. PubMed ID: 20888031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.